Valuation Indivior Pharmaceuticals, Inc. London S.E.

Equities

Market Closed - London S.E. Other stock markets 11:35:04 2025-07-24 EDT			5-day change	1st Jan Change
1,238.00 ^GBX	+1.56%		+5.27%	+20.90%

05-20	Indivior Pharmaceuticals Announces Findings From Real-World Evidence Studies on Monthly Injectable Buprenorphine	CI
05-04	Indivior Pharmaceuticals Enters $175 Million Accelerated Share Repurchase Agreement	MT

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Capitalization ¹	2,423	2,969	2,085	1,553	4,480	4,586	-	-
Change	-	22.54%	-29.76%	-25.5%	188.39%	2.37%	-	-
Enterprise Value (EV) ¹	1,563	2,435	2,008	1,567	4,604	4,641	4,183	3,658
Change	-	55.81%	-17.52%	-21.95%	193.72%	0.8%	-9.87%	-12.54%
P/E ratio	12.8x	-57.2x	1,527x	-34.5x	21.9x	11.8x	10.9x	9.64x
PBR	-	59.3x	-	-8.02x	-45.8x	-	-	-
PEG	-	0x	-15x	0x	-0x	0.1x	1.31x	0.7x
Capitalization / Revenue	3.06x	3.29x	1.91x	1.31x	3.62x	3.65x	3.56x	3.34x
EV / Revenue	1.98x	2.7x	1.84x	1.32x	3.72x	3.69x	3.25x	2.66x
EV / EBITDA	7.74x	10.8x	6.97x	4.64x	10.8x	7.11x	6.06x	5.09x
EV / EBIT	8.36x	11.5x	7.47x	5.02x	11.1x	7.45x	6.54x	5.24x
EV / FCF	4.61x	-10.7x	-4.86x	-196x	-49.5x	12.9x	8.63x	6.79x
FCF Yield	21.7%	-9.32%	-20.6%	-0.51%	-2.02%	7.77%	11.6%	14.7%
Dividend per Share ²	-	-	-	-	-	-	-	-
Rate of return	-	-	-	-	-	-	-	-
EPS ²	1.35	-0.38	0.01	-0.36	1.64	3.175	3.44	3.9
Distribution rate	-	-	-	-	-	-	-	-
Net sales ¹	791	901	1,093	1,188	1,239	1,258	1,287	1,374
EBITDA ¹	202	225	288	338	428	652.9	690.5	718.4
EBIT ¹	187	212	269	312	415	623.3	640	698.8
Net income ¹	205	-53	2	-48	210	414.5	454.9	517.4
Net Debt ¹	-860	-534	-77	14	124	54.5	-403.4	-928
Reference price ²	17.25	21.75	15.27	12.43	35.88	37.62	37.62	37.62
Nbr of stocks (in thousands)	140,437	136,489	136,551	124,970	124,854	121,922	-	-
Announcement Date	2/16/22	2/16/23	2/22/24	2/20/25	2/26/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
ELI LILLY AND COMPANY	33.11x	12.04x	24.78x	0.6%	1,009B
JOHNSON & JOHNSON	24.88x	5.74x	15.6x	2.29%	560B
ABBVIE INC.	27.82x	6.77x	13.84x	3.02%	401B
ROCHE HOLDING AG	17.55x	4.34x	10.65x	3.07%	328B
ASTRAZENECA PLC	23.42x	4.85x	13.81x	1.8%	288B
NOVARTIS AG	20.62x	5.32x	12.95x	3.06%	272B
NOVO NORDISK A/S	12.56x	4.71x	9.62x	4%	194B
AMGEN INC.	22.73x	6.08x	10.62x	2.89%	189B
GILEAD SCIENCES, INC.	-46.22x	5.58x	31.48x	2.51%	160B
Average	15.16x	6.16x	15.93x	2.58%	377.96B
Weighted average by Cap.	22.32x	7.44x	17.40x	2.11%